The studies on autophagy in prostate cancer that have been discussed in the current review range from interfering with ULK1, ULK2, ATG3, ATG4B, ATG4D, ATG5, BECLIN1, ATG7, LC3A, ATG16L1, FIP200, TFEB, LAMP2A, or p62. While it is good that many different ATGs or autophagy regulators have been targeted in these studies, the problem is that the various studies have chosen just one or two targets in a seemingly random way to infer causality. Here, MAP1LC3A is linked to prostate cancer.